Keyphrases
Acute Leukemia
5%
Acute Lymphoblastic Leukemia
10%
Acute Myeloid Leukemia
50%
Acute Myeloid Leukemia Stem Cells
10%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
10%
Aplasia
30%
Bone Marrow
10%
Bone Marrow Cells
5%
Bone Marrow Transplantation
15%
Camelid Antibody
10%
Cancer Cells
5%
CD123
50%
CD33
50%
Cell of Origin
5%
Cell Targeting
5%
Cell Treatment
5%
Chemotherapy
5%
Chemotherapy Agents
5%
Chimeric Antigen Receptor T Cells (CAR-T)
50%
Chimeric Antigen Receptor T-cell Therapy
25%
Clinical Activity
5%
Clinical Relapse
5%
CLL-1
100%
Co-target
10%
Early Efficacy
10%
Effective Treatment
5%
First-in-human Study
10%
Healthy Cells
5%
Hematological Malignancies
5%
High Mortality
5%
High-dose Chemotherapy
5%
Immune System
5%
Immune Therapy
5%
Initial Treatment
5%
Intensive Chemotherapy
10%
Intrapatient Heterogeneity
10%
Leukemia
15%
Leukemia-associated Antigen
10%
Leukemic Stem Cells
20%
Long-term Remission
10%
Long-term Survival
5%
Marrow
15%
Myeloid Leukemia
5%
Myeloid Precursors
10%
Normal Bone Marrow
10%
Rare Forms
10%
Reduced-intensity Conditioning
10%
Relapsed or Refractory Acute Myeloid Leukemia
5%
Remission
5%
Salvage Chemotherapy
5%
Single Vector
10%
Stem Cell Population
5%
Success Rate
5%
Suicide Gene
5%
T Cell Targeting
100%
Therapy Options
10%
Therapy Treatment
5%
Tumor Heterogeneity
5%
Young Subgroup
10%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
8%
Acute Myeloid Leukemia
50%
Aplasia
25%
Bone Marrow Transplantation
12%
CD33 Antigen
8%
Chemotherapy Agent
8%
Chimeric Antigen Receptor T-Cell
50%
Chimeric Antigen Receptor T-Cell Immunotherapy
20%
Disease
12%
Hematopoietic Stem Cell Transplantation
16%
Leukemia
12%
Leukemia Antigen
8%
Reduced Intensity Conditioning
8%
Stem Cell
8%
Tumour Heterogeneity
8%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
7%
Acute Myeloid Leukemia
50%
Aplasia
23%
Camelid
7%
CD33 Antigen
7%
Chemotherapy
11%
Chemotherapy Agent
7%
Chimeric Antigen Receptor
50%
Disease
11%
Leukemia
11%
Leukemia Antigen
7%
Malignant Neoplasm
7%
Remission
7%